Drug Pricing Investigation

Publication

Drug Pricing Investigation

Abstract

This report summarizes the findings of a nearly three-year investigation by the Committee on Oversight and Reform into pricing and business practices for branded prescription drugs in the United States. The investigation focused on ten companies selling 12 drugs with high costs to the Medicare program. The investigation reveals unsustainable, unjustified, and unfair pricing practices that strain the U.S. healthcare system and leave millions unable to afford essential medications. The report includes insights into tactics used by drug companies, such as suppressing competition, and highlights the impact of high drug prices on patients and federal health care programs.